Travere Therapeutics (TVTX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Travere Therapeutics (TVTX) do?
Travere Therapeutics Inc (TVTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells prescription medicines including Filspari for rare kidney diseases and Thiola for cystinuria. Develops and commercializes specialized therapies targeting rare kidney and metabolic diseases. It is worth $4.64B on the market and sold $651.18M over the last year.
- Market cap
- $4.64B
- P/E ratio
- None (reported a loss)
- Annual sales
- $651.18M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 19, 2026
Brands and businesses behind TVTX
- Filspari: Generates revenue by selling oral prescription tablets to treat kidney damage from primary IgA nephropathy.
- Thiola EC: Earns revenue selling delayed release tablets to prevent cystine stone formation in cystinuria patients.
TVTX’s flags, in plain English
Each flag is a number from Travere Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.
Wide Gross Margin
Gross margin of 90.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Still Climbing
Sales up 19.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Debt Is Driving
Heavy debt, 2729% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about TVTX
How big is Travere Therapeutics?
Travere Therapeutics’ market cap is $4.64B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $651.18M: what customers paid the company over the last year, before any costs.
What is TVTX’s P/E ratio?
TVTX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with TVTX?
The business depends heavily on commercial adoption of Filspari while operating with persistent yearly net losses. That is one risk on Travere Therapeutics’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Travere Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TVTX’s filings on SEC.gov. The Margin Monkey is research, not advice.
